Sinonasal Symptoms in COPD: Burden and Associations with Clinical Markers of Disease

References

• Valiulis A, Bousquet J, Veryga A, et al. Vilnius declaration on chronic respiratory diseases: multisectoral care pathways embedding guided self-management, mHealth and air pollution in chronic respiratory diseases. Clin Transl Allergy. 2019;9:7. doi:10.1186/s13601-019-0242-2
   PubMed Web of Science ®Google Scholar
• Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• GOLD Reports. Global initiative for chronic obstructive lung disease; 2022. Available from: www.goldcopd.org. Accessed September 1, 2022.
   Google Scholar
• Gonçalves I, Guimarães MJ, van Zeller M, Menezes F, Moita J, Simão P. Clinical and molecular markers in COPD. Pulmonology. 2018;24(4):250–259. doi:10.1016/j.pulmoe.2018.02.005
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax. 2000;55(Suppl2):S26–S27. doi:10.1136/thorax.55.suppl_2.s26
   PubMed Web of Science ®Google Scholar
• Tiotiu A, Novakova P, Baiardini I, et al. Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document. J Asthma. 2021:1–16. doi:10.1080/02770903.2021.1879130
   PubMed Web of Science ®Google Scholar
• Caillaud D, Chanez P, Escamilla R, et al. Association of chronic nasal symptoms with dyspnoea and quality-of-life impairment in chronic obstructive pulmonary disease. Respirology. 2014;19(3):346–352. doi:10.1111/resp.12224
   PubMed Web of Science ®Google Scholar
• Hurst JR, Wilkinson TMA, Donaldson GC, Wedzicha JA. Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). Article. Respir Med. 2004;98(8):767–770. doi:10.1016/j.rmed.2004.01.010
   PubMed Web of Science ®Google Scholar
• Montnemery P, Svensson C, Adelroth E, et al. Prevalence of nasal symptoms and their relation to self-reported asthma and chronic bronchitis/emphysema. Eur Respir J. 2001;17(4):596–603. doi:10.1183/09031936.01.17405960
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Lloyd-Owen SJ, Rapado F, et al. Relationship between chronic nasal and respiratory symptoms in patients with COPD. Respir Med. 2003;97(8):909–914. doi:10.1016/S0954-6111(03)00114-8
   PubMed Web of Science ®Google Scholar
• Oie MR, Dahlslett SB, Sue-Chu M, Helvik AS, Steinsvag SK, Thorstensen WM. Rhinosinusitis without nasal polyps in COPD. ERJ Open Res. 2020;6(2):00015–2020. doi:10.1183/23120541.00015-2020
   PubMedGoogle Scholar
• Luu K, Sutherland J, Crump T, Liu G, Janjua A. The impact of chronic airway disease on symptom severity and global suffering in Canadian rhinosinusitis patients. J Otolaryngol Head Neck Surg. 2018;47(1):40. doi:10.1186/s40463-018-0287-6
   PubMed Web of Science ®Google Scholar
• Hens G, Vanaudenaerde BM, Bullens DM, et al. Sinonasal pathology in nonallergic asthma and COPD: “united airway disease” beyond the scope of allergy. Allergy. 2008;63(3):261–267. doi:10.1111/j.1398-9995.2007.01545.x
   PubMed Web of Science ®Google Scholar
• Bergqvist J, Andersson A, Olin AC, et al. New evidence of increased risk of rhinitis in subjects with COPD: a longitudinal population study. Int J Chron Obstruct Pulmon Dis. 2016;11:2617–2623. doi:10.2147/copd.S115086
   PubMed Web of Science ®Google Scholar
• Arndal E, Sorensen AL, Lapperre TS, et al. Chronic rhinosinusitis in COPD: a prevalent but unrecognized comorbidity impacting health related quality of life. Respir Med. 2020;171:106092. doi:10.1016/j.rmed.2020.106092
   PubMed Web of Science ®Google Scholar
• Hansen AG, Helvik AS, Thorstensen WM, et al. Paranasal sinus opacification at MRI in lower airway disease (the HUNT study-MRI). Eur Arch Otorhinolaryngol. 2016;273(7):1761–1768. doi:10.1007/s00405-015-3790-7
   PubMed Web of Science ®Google Scholar
• Øie MR, Sue-Chu M, Helvik A-S, Steinsvåg SK, Steinsbekk S, Thorstensen WM. Rhinosinusitis without nasal polyps is associated with poorer health-related quality of life in COPD. Respir Med. 2021;189:106661. doi:10.1016/j.rmed.2021.106661
   PubMed Web of Science ®Google Scholar
• Fokkens WJ, Lund VJ, Mullol J, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl. 2012;23:1–298.
   Google Scholar
• Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63(Suppl 86):8–160. doi:10.1111/j.1398-9995.2007.01620.x
   PubMed Web of Science ®Google Scholar
• Erskine SE, Hopkins C, Clark A, et al. SNOT-22 in a control population. Clin Otolaryngol. 2017;42(1):81–85. doi:10.1111/coa.12667
   PubMed Web of Science ®Google Scholar
• Lange B, Thilsing T, Al-kalemji A, Baelum J, Martinussen T, Kjeldsen A. The Sino-Nasal outcome test 22 validated for Danish patients. Dan Med Bull. 2011;58(2):A4235.
   PubMedGoogle Scholar
• Browne JP, Hopkins C, Slack R, Cano SJ. The Sino-Nasal Outcome Test (SNOT): can we make it more clinically meaningful? Otolaryngol Head Neck Surg. 2007;136(5):736–741. doi:10.1016/j.otohns.2007.01.024
   PubMed Web of Science ®Google Scholar
• Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. doi:10.1378/chest.93.3.580
   PubMed Web of Science ®Google Scholar
• Martin Nguyen A, Bacci ED, Vernon M, et al. Validation of a visual analog scale for assessing cough severity in patients with chronic cough. Ther Adv Respir Dis. 2021;15:17534666211049743. doi:10.1177/17534666211049743
   Web of Science ®Google Scholar
• American Thoracic Society Committee. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117. doi:10.1164/ajrccm.166.1.at1102
   PubMed Web of Science ®Google Scholar
• Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(10):1005–1012. doi:10.1056/NEJMoa021322
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. Respir Med. 1991;85(Suppl B):25–37. doi:10.1016/s0954-6111(06)80166-6
   PubMed Web of Science ®Google Scholar
• Ware JE Jr. SF-36 Health survey update. Spine. 2000;25(24):3130–3139. doi:10.1097/00007632-200012150-00008
   PubMed Web of Science ®Google Scholar
• Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT) scores. BMC Pulm Med. 2011;11:42. doi:10.1186/1471-2466-11-42
   PubMed Web of Science ®Google Scholar
• Müllerová H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive pulmonary disease managed in primary care. PLoS One. 2014;9(1):e85540. doi:10.1371/journal.pone.0085540
   PubMed Web of Science ®Google Scholar
• Scarlata S, Finamore P, Laudisio A, et al. Association between frailty index, lung function, and major clinical determinants in chronic obstructive pulmonary disease. Aging Clin Exp Res. 2021;33(8):2165–2173. doi:10.1007/s40520-021-01878-z
   PubMed Web of Science ®Google Scholar
• Andrianopoulos V, Wouters EF, Pinto-Plata VM, et al. Prognostic value of variables derived from the six-minute walk test in patients with COPD: results from the ECLIPSE study. Respir Med. 2015;109(9):1138–1146. doi:10.1016/j.rmed.2015.06.013
   PubMed Web of Science ®Google Scholar
• Marin JM, Carrizo SJ, Casanova C, et al. Prediction of risk of COPD exacerbations by the BODE index. Respir Med. 2009;103(3):373–378. doi:10.1016/j.rmed.2008.10.004
   PubMed Web of Science ®Google Scholar
• Schumacher MJ. Nasal dyspnea: the place of rhinomanometry in its objective assessment. Am J Rhinol. 2004;18(1):41–46. doi:10.1177/194589240401800109
   PubMedGoogle Scholar
• Hurst JR, Kuchai R, Michael P, Perera WR, Wilkinson TM, Wedzicha JA. Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. Clin Physiol Funct Imaging. 2006;26(4):251–256. doi:10.1111/j.1475-097X.2006.00683.x
   PubMed Web of Science ®Google Scholar
• Koo HK, Park SW, Park JW, et al. Chronic cough as a novel phenotype of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:1793–1801. doi:10.2147/copd.S153821
   PubMed Web of Science ®Google Scholar
• Pratter MR. Chronic upper airway cough syndrome secondary to rhinosinus diseases (previously referred to as postnasal drip syndrome): ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1):63s–71s. doi:10.1378/chest.129.1_suppl.63S
   PubMed Web of Science ®Google Scholar
• Dąbrowska M, Arcimowicz M, Grabczak EM, et al. Chronic cough related to the upper airway cough syndrome: one entity but not always the same. Eur Arch Otorhinolaryngol. 2020;277(10):2753–2759. doi:10.1007/s00405-020-06071-y
   PubMed Web of Science ®Google Scholar
• Chien CY, Tai SY, Wang LF, Lee CT. Chronic obstructive pulmonary disease predicts chronic rhinosinusitis without nasal polyps: a population-based study. Am J Rhinol Allergy. 2015;29(3):e75–80. doi:10.2500/ajra.2015.29.4172
   PubMed Web of Science ®Google Scholar
• Huerta A, Donaldson GC, Singh R, et al. Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2015;12(7):997–1004. doi:10.1513/AnnalsATS.201408-359OC
   PubMed Web of Science ®Google Scholar
• Calabrese C, Costigliola A, Maffei M, et al. Clinical impact of nasal budesonide treatment on COPD patients with coexistent rhinitis. Int J Chron Obstruct Pulmon Dis. 2018;13:2025–2032. doi:10.2147/copd.S165857
   PubMed Web of Science ®Google Scholar
• Hanania NA, O’Donnell DE. Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chron Obstruct Pulmon Dis. 2019;14:1127–1138. doi:10.2147/copd.S188141
   PubMed Web of Science ®Google Scholar
• Polkey MI, Rabe KF. Chicken or egg: physical activity in COPD revisited. Eur Respir J. 2009;33(2):227–229. doi:10.1183/09031936.00176808
   PubMed Web of Science ®Google Scholar
• Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a Prospective Cohort Study. Chest. 2011;140(2):331–342. doi:10.1378/chest.10-2521
   PubMed Web of Science ®Google Scholar
• Håkansson K, Konge L, Thomsen SF, Backer V, von Buchwald C. Sinonasal inflammation in COPD: a systematic review. Eur Respir J. 2013;42(5):1402–1411. doi:10.1183/09031936.00119712
   PubMed Web of Science ®Google Scholar
• Yang X, Xu Y, Jin J, Li R, Liu X, Sun Y. Chronic rhinosinusitis is associated with higher prevalence and severity of bronchiectasis in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:655–662. doi:10.2147/COPD.S124248
   PubMed Web of Science ®Google Scholar
• Piotrowska VM, Piotrowski WJ, Kurmanowska Z, Marczak J, Górski P, Antczak A. Rhinosinusitis in COPD: symptoms, mucosal changes, nasal lavage cells and eicosanoids. Int J Chron Obstruct Pulmon Dis. 2010;5:107–117. doi:10.2147/copd.s8862
   PubMedGoogle Scholar
• Obling N, Backer V, Hurst JR, Bodtger U. Upper airway symptoms associate with the eosinophilic phenotype of COPD. ERJ Open Res. 2021;7(3):00184–2021. doi:10.1183/23120541.00184-2021
   PubMedGoogle Scholar
• Gelardi M, Bocciolini C, Notargiacomo M, et al. Chronic rhinosinusitis with nasal polyps: how to identify eligible patients for biologics in clinical practice. Acta Otorhinolaryngol Ital. 2022;42(1):75–81. doi:10.14639/0392-100x-n1699
   PubMed Web of Science ®Google Scholar
• Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respir Med. 2001;95(12):999–1002. doi:10.1053/rmed.2001.1195
   PubMed Web of Science ®Google Scholar
• Smith JA, Kitt MM, Butera P, et al. Gefapixant in two randomised dose-escalation studies in chronic cough. Eur Respir J. 2020;55(3):1901615. doi:10.1183/13993003.01615-2019
   PubMed Web of Science ®Google Scholar